Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
P/E
Price to Earnings
Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.
Market Cap | P/E | ||||
---|---|---|---|---|---|
US |
Arcturus Therapeutics Holdings Inc
NASDAQ:ARCT
|
730m USD | -24.6 | ||
US |
Abbvie Inc
NYSE:ABBV
|
283.3B USD | 58.8 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
164.8B USD | 43.8 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.9B USD | 29.8 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
105.3B USD | 27.3 | ||
AU |
CSL Ltd
ASX:CSL
|
135.1B AUD | 36 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.9B USD | 167.1 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
46.7B USD | -7.8 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | -57.5 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
32B USD | 27.4 | ||
KR |
Celltrion Inc
KRX:068270
|
40.3T KRW | 75.3 |
P/E Forward Multiples
Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.